Search results
Showing 1 to 15 of 74 results for cystic fibrosis
This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS168Show all sections
All NICE products on cystic fibrosis. Includes any guidance, advice and quality standards.
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Evidence-based recommendations on colistimethate sodium (Colobreathe) and tobramycin (TOBI Podhaler) dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis in people of 6 years and over.
Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
This indicator covers patient adherence to nebulised therapy in cystic fibrosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic
Topic prioritisation
Cystic fibrosis: adherence to therapy (chronic pseudomonas acquisition) (IND294)
This indicator covers normative adherence to nebulised therapy in cystic fibrosis for patients with chronic pseudomonas acquisition. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes